US considers Section 232 probe of Swiss pharma, risking tariffs up to 39%
The US is signaling a potential formal trade investigation into Switzerland’s pharmaceutical industry under Section 232. Pharmaceuticals are nearly half of Swiss exports to the US, about $35.5 billion in 2024.
Tariffs have been volatile. Under Section 232, US tariffs on Swiss goods peaked at 39% in August 2025, although pharmaceuticals were initially carved out. A US–Swiss deal in November 2025 then capped pharmaceutical tariffs at 15%. In return, Swiss firms pledged major investments in the US: Roche $50B and Novartis $23B, with total commitments around $200B to expand US manufacturing and operations.
Why this matters now: a new Section 232 review could frame Swiss pharma imports as a national-security risk, allowing wider restrictions. The timing also echoes Washington’s broader pharma scrutiny. On June 18, 2026, the US began a Section 301 investigation into Germany’s drug pricing policies.
Companies are already adjusting. Novartis has built US stockpiles to keep supply running through mid-2026, with local manufacturing planned within 3–4 years. Roche is pursuing similar domestic production.
For investors, the near-term impact is likely margin pressure from capex, supply chain changes, and regulatory compliance. The key trading catalyst is whether the 15% tariff cap holds. If tariffs return toward 39% or higher, it could hit European drug makers beyond Roche and Novartis, including AstraZeneca, Sanofi, and GSK.
Neutral
This is a macro/trade-policy risk story focused on European pharma, not crypto fundamentals. If the US expands Section 232 tools and tariffs threaten a return toward 39%, it can worsen investor risk appetite for European equities and translate into broader “risk-off” conditions that sometimes spill over into crypto via correlation (e.g., during tariff escalation headlines). However, the article contains no direct cryptocurrency, stablecoin, exchange, or on-chain protocol catalyst.
Short term: traders may react to tariff headline risk by moving toward safer macro exposures; that can create mild downside volatility for crypto, especially for assets that track liquidity and global risk sentiment.
Long term: the magnitude of capital reallocation (Roche and Novartis shifting tens of billions toward US manufacturing) is ultimately a corporate execution and regulation story. Unless it triggers a sustained recessionary impact or broad financial stress, crypto market structure is likely unchanged. A key monitor is whether Washington’s pharma investigations broaden rapidly (similar to how past policy escalations can tighten financial conditions), or whether the 15% tariff cap holds, reducing headline-driven volatility.